Brilinta (Ticagrelor)

Name: Brilinta
Brand: AstraZeneca
SKU: 6768
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Brilinta

Manufacturer: AstraZeneca

Country: Canada

Dosage: 60 mg

Qty-Price (USD):

Type:

Product: Brilinta

Manufacturer: AstraZeneca

Country: India

Dosage: 60 mg

Qty-Price (USD):

Type:

Product: Brilinta

Manufacturer: AstraZeneca

Country: Canada

Dosage: 90 mg

Qty-Price (USD):

Type:

Product: Brilinta

Manufacturer: AstraZeneca

Country: India

Dosage: 90 mg

Qty-Price (USD):

Type:

Product: Brilinta (ON BACKORDER)

Manufacturer: AstraZeneca

Country: Turkey

Dosage: 90 mg

Qty-Price (USD):

Generic Equivalent of Brilinta

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Ticagrelor

Manufacturer: Generic

Country: Canada

Dosage: 60 mg

Qty-Price (USD):

Type:

Product: Ticagrelor

Manufacturer: Generic

Country: India

Dosage: 60 mg

Qty-Price (USD):

Type:

Product: Ticagrelor

Manufacturer: Generic

Country: India

Dosage: 60 mg

Qty-Price (USD):

Type:

Product: Ticagrelor

Manufacturer: Generic

Country: Canada

Dosage: 90 mg

Qty-Price (USD):

Type:

Product: Ticagrelor

Manufacturer: Generic

Country: India

Dosage: 90 mg

Qty-Price (USD):

Brilinta Information

medically reviewed by Carol Hou (BSc. Pharm) on June 27, 2025.

A licensed pharmacist (Licensed Community Pharmacies Directory | College of Pharmacists of British Columbia) with over 20 years of experience in medication management, specifically medication safety, she has reviewed the information for accuracy and completeness.

Brilinta and Ticagrelor at CanadaPharmacyOnline.com

The brand-name drug Brilinta (ticagrelor) is manufactured by AstraZeneca and is available in various countries, including Canada, Turkey, and India.

Generic ticagrelor is sourced from manufacturers that meet applicable regulatory standards. The specific manufacturer of your dispensed medication may vary.

Important Information about Generic Ticagrelor:

Generic ticagrelor contains the same active ingredient as brand-name Brilinta and is required to meet the same safety, effectiveness, and quality standards. This means it is designed to work in the same way. Studies have shown that generic ticagrelor is bioequivalent to brand-name Brilinta, meaning they have similar absorption rates and reach similar concentrations in the bloodstream. However, individual responses to medication can vary due to factors such as metabolism, genetics, and other health conditions.

For more information about generic drug approval and bioequivalence, you can visit the FDA website: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

Dosage:

Brand Brilinta and generic ticagrelor are commonly available in 60 mg and 90 mg oral tablets.

Your doctor will determine the appropriate dose based on your individual needs and medical conditions.

Usage:

Brilinta (ticagrelor) is primarily used to reduce the risk of serious cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with acute coronary syndrome (ACS), a history of heart attack, or coronary artery disease at high risk. In the setting of ACS, it helps prevent subsequent cardiovascular events. Typically administered with low-dose aspirin, Brilinta inhibits platelet aggregation, thereby avoiding the formation of dangerous blood clots.

Mechanism of Action:
Ticagrelor is a direct-acting, reversibly binding cyclopentyltriazolopyrimidine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor. Unlike some other P2Y12 inhibitors, ticagrelor does not require metabolic activation. It binds to the ADP receptor through an allosteric interaction, rapidly inhibiting ADP-mediated platelet activation and aggregation, thereby preventing thrombus formation. Ticagrelor is metabolized to an active metabolite, AR-C124910, which also contributes to the antiplatelet effect, and its activity is considered comparable to the parent drug.

Take Brilinta exactly as your doctor prescribes, following the instructions in the product monograph in Canada. Consult your doctor for personalized guidance and safe use.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before taking Brilinta, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below outlines potential side effects associated with Brilinta (ticagrelor). It is not an exhaustive list, and individual reactions can vary.

Common side effects - These are some common side effects of Brilinta, but others are possible. Contact your doctor promptly if any side effects are persistent, worsening, or concerning, or if you experience any other concerning symptoms.
• Back pain
• Bleeding: This is the most significant side effect as Brilinta works by preventing blood clots.
o Blood in urine (pink, red, or brown)
o Black or tarry stools
o Bleeding that takes longer to stop
o Bleeding gums
o Bruises more easily
o Coughing up blood
o Increased menstrual flow or vaginal bleeding
o Nosebleeds
o Pinpoint red spots on the skin
o Unusual bleeding or bruising
o Vomiting blood or material that looks like coffee grounds
• Confusion
• Cough
• Diarrhea
• Dizziness: Dizziness is a common side effect of Brilinta and can be associated with its pharmacological effect, including potential bradycardia (slowed heart rate) and ventricular pauses. While often transient, persistent, or severe dizziness should be promptly evaluated by a healthcare professional to rule out significant cardiac rhythm disturbances.
• Fainting
• Fatigue
• Headache
• Nausea: Taking Brilinta with food may help prevent nausea.
• Rash
• Shortness of breath (Dyspnea): Dyspnea is a well-recognized and relatively common side effect of Brilinta, often occurring early in treatment. While frequently mild and transient, it can be a reason for discontinuation in some patients. New, worsened, or persistent dyspnea should be evaluated to differentiate between a typical side effect and a sign of underlying cardiopulmonary issues or a more serious adverse reaction to the drug. • Slow heart rate (Bradycardia): This is a less common but potentially serious side effect.

Serious Side Effects: These are rare but potentially severe side effects. Seek immediate medical attention or call emergency services if you experience any of the following:
• Allergic reactions: These can include swelling of the face, throat, lips, tongue, hands, or feet.
• Irregular breathing patterns, such as central sleep apnea or Cheyne-Stokes respiration.
• New or worsening shortness of breath
• Severe or uncontrollable bleeding
• Signs of internal bleeding (e.g., severe abdominal pain, vomiting blood, black tarry stools)
• Signs of a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face, lips, tongue, or throat)
• Symptoms of Thrombotic Thrombocytopenic Purpura (TTP), a rare blood disorder (e.g., fever, purplish spots on the skin or in the mouth, yellowing of the skin or eyes, unexplained extreme tiredness or confusion)
• Symptoms of a slow or irregular heartbeat (e.g., chest pain, dizziness, fainting, lightheadedness)

Contraindications:

The following is not an exhaustive list of contraindications. Before starting Brilinta, it is crucial to discuss all your medical conditions, past and present, and all medications you are taking with your doctor or pharmacist.

Brilinta should not be used if you:
• Are allergic to ticagrelor or any of the inactive ingredients in the tablet.
• Are undergoing planned (elective) coronary artery bypass graft (CABG) surgery: Due to the increased risk of bleeding, it is generally recommended to discontinue Brilinta at least 5 days before elective CABG surgery. In urgent or emergent CABG cases, deciding to proceed with surgery while on ticagrelor involves careful consideration of the bleeding risk versus the urgency of the procedure.
• Have active pathological bleeding, Such as from a peptic ulcer or current bleeding in the brain. Brilinta can worsen this bleeding.
• Have a history of intracranial hemorrhage (ICH) or current pathological bleeding (e.g., active peptic ulcer, active intracranial hemorrhage): Brilinta is contraindicated in these situations due to the significantly increased risk of recurrent or exacerbated bleeding.
• Have severe hepatic (liver) impairment: Brilinta is contraindicated in patients with severe hepatic impairment because it has not been studied in this population, and the potential for increased exposure to the drug and subsequent bleeding risk is significant.

Tell your doctor about all of your medical conditions, past and present, before starting Brilinta. This is crucial because certain conditions can affect whether Brilinta is right for you. These conditions may include, but are not limited to:
• Bradyarrhythmias: Brilinta can cause ventricular pauses and bradyarrhythmias (slow heart rate), including AV block. Exercise caution when prescribing it to patients with a history of sick sinus syndrome, 2nd or 3rd-degree AV block, or bradycardia-related syncope not protected by a pacemaker, as they may be at increased risk.
• Dyspnea (Shortness of Breath): Dyspnea has been reported with Brilinta use. Care should be taken when prescribing it to patients with a history of dyspnea. If new, prolonged, or worsened dyspnea is related to Brilinta, treatment should continue with monitoring if possible. Discontinuation may be considered if dyspnea is intolerable.
• Heart Rhythm Problems: Brilinta can cause bradycardia (slow heart rate) and ventricular pauses. It is contraindicated or should be used with extreme caution in patients with certain pre-existing heart rhythm disorders, such as sick sinus syndrome, 2nd or 3rd-degree AV block without a pacemaker, or bradycardia-related syncope not protected by a pacemaker. Caution is also advised with other medications that can lower the heart rate.
• History of Stroke or Transient Ischemic Attack (TIA): Brilinta is indicated to reduce the risk of subsequent stroke in patients who have experienced an acute ischemic stroke or TIA. However, caution should be exercised in patients with a remote history of stroke, particularly hemorrhagic stroke, due to the increased risk of bleeding associated with ticagrelor.
• Liver Dysfunction (Moderate): Brilinta should be used with caution in patients with moderate liver impairment due to the probable increase in exposure to the drug. The risks and benefits of treatment should be carefully considered. No dosage adjustment is needed for mild liver impairment.
• Lung Disease or Breathing Problems (e.g., Asthma, COPD): Use Brilinta with caution as it may worsen these conditions.
• Recent Surgery (including dental procedures): Brilinta may increase the risk of bleeding during or after surgery. It is generally recommended to stop Brilinta 5 days before surgery, with a major risk of bleeding.
• Renal Impairment: No dosage adjustment is generally needed for patients with renal impairment. However, close monitoring is recommended in dialysis patients as they have not been specifically studied.
• Sleep Apnea: Central sleep apnea has been reported in some patients taking Brilinta, particularly those with underlying heart conditions or a history of stroke.

Drug Interactions:

Before taking Brilinta, it is essential to discuss all potential risks and interactions with your doctor or pharmacist. For complete and up-to-date information, refer to the Brilinta consumer information leaflet | AstraZeneca.ca: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/brilinta-consumer-information-leaflet-en.pdf

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, and herbal supplements. It is also important to inform your doctor about any herbal teas, recreational drugs, or significant dietary changes you are making, as these could potentially interact with Brilinta. Brilinta may interact with other medicines that also affect blood clotting, as well as different types of drugs, but is not limited to:

Increased Risk of Bleeding:
• Aspirin: Low-dose aspirin (typically 75-100 mg daily) is recommended in combination with Brilinta, except when contraindicated. Higher maintenance doses of aspirin (>100 mg daily) are not recommended and may reduce the efficacy of Brilinta. Patients should avoid taking new medications containing aspirin or increasing their aspirin dose without consulting their doctor.
• Blood Thinners (Anticoagulants): Using Brilinta with blood thinners such as warfarin (Coumadin), heparin, apixaban (Eliquis), dabigatran (Pradaxa), or rivaroxaban (Xarelto) can significantly raise the risk of bleeding.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): This includes over-the-counter medications like ibuprofen (Advil, Motrin), naproxen (Aleve), and prescription NSAIDs like celecoxib (Celebrex) and meloxicam (Mobic). They can increase the risk of bleeding when taken with Brilinta.
• Other Antiplatelet Drugs: Combining Brilinta with other antiplatelet drugs like clopidogrel (Plavix), prasugrel (Effient), or dipyridamole can increase the risk of bleeding.

Drugs Affecting Brilinta Levels:
• Strong CYP3A4 Inhibitors: These drugs can significantly increase the levels of Brilinta in your body, potentially leading to a higher risk of side effects like shortness of breath. Examples include:
o Ketoconazole, itraconazole, voriconazole (antifungal medications)
o Clarithromycin (antibiotic)
o Ritonavir, saquinavir, nelfinavir, indinavir, atazanavir (antiviral medications)
o Nefazodone (antidepressant)
o Telithromycin (antibiotic)
• Strong CYP3A4 Inducers: These drugs can significantly decrease the levels of Brilinta in your body, potentially reducing its effectiveness. Examples include:
o Rifampin (antibiotic)
o Phenytoin, carbamazepine, phenobarbital, primidone (anti-seizure medications)
o Apalutamide, enzalutamide (prostate cancer medications)

Other Potential Interactions:
• Alprazolam (Xanax): Brilinta may increase the levels and effects of alprazolam.
• Certain Organ Transplant Drugs: Brilinta may interact with cyclosporine and sirolimus, potentially increasing the levels of either drug.
• Certain Antivirals: Some antiviral medications (e.g., ritonavir, nelfinavir, atazanavir) can increase Brilinta levels.
• Certain Antifungals: Some antifungal medications (e.g., ketoconazole, itraconazole, voriconazole) can increase Brilinta levels.
• Certain Seizure Medications: Anti-seizure medications (e.g., carbamazepine, phenytoin, phenobarbital) can decrease Brilinta levels.
• Digoxin (Lanoxin): Brilinta can increase digoxin levels in the blood, requiring monitoring.
• Opioids: Opioids can delay and reduce the absorption of oral P2Y12 inhibitors, including ticagrelor, likely due to delayed gastric emptying. In the acute setting of acute coronary syndrome (ACS), where rapid antiplatelet effect is critical, this interaction can be clinically significant and may lead to a delayed onset of action of ticagrelor. Healthcare providers should be aware of this potential delay, especially in patients requiring urgent percutaneous coronary intervention (PCI), and consider alternative antiplatelet strategies or intravenous antiplatelet agents if a rapid effect is paramount. The impact may be less acute for chronic stable patients, but the overall exposure could still be altered.
• Statins: Brilinta can increase the blood levels of certain statins, such as simvastatin (Zocor) and lovastatin (Altoprev), potentially increasing the risk of statin-related side effects like muscle pain. Avoid simvastatin and lovastatin doses greater than 40 mg while taking Brilinta. Other statins like atorvastatin (Lipitor) and rosuvastatin (Crestor) may not require dose adjustments.

Alcohol
Moderate alcohol consumption is generally acceptable while taking Brilinta. However, excessive alcohol intake can increase the risk of bleeding and gastrointestinal issues, and this risk may be amplified if you are also taking aspirin.

Pregnancy and Breastfeeding

Use of Brilinta during pregnancy is not recommended. Studies in animals have shown reproductive toxicity. Women of childbearing potential should use effective contraception during treatment with Brilinta. Breastfeeding is not recommended during treatment with Brilinta. Animal studies have shown that ticagrelor and its active metabolite are excreted in milk. The potential risk to a breastfed infant cannot be excluded.

Frequently Asked Questions about Brilinta at Canada Pharmacy Online:

Why is Brilinta more affordable in Canada than in the United States?

Prescription drug prices, including Brilinta, are generally lower in Canada than in the US due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower costs compared to the U.S., where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/

What is the difference between Brilinta 60 mg and 90 mg?

The difference in dosage represents the different amount of the same active ingredient (ticagrelor) present in each tablet.

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy focuses on offering you the lowest prices on high-quality products.

How do I order from your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Is there a limit on how many tablets I am allowed to order at one time?

CanadaPharmacyOnline.com can only dispense a maximum of three months of Brilinta at once, per your doctor's prescription.

Can I buy over the counter from you?

No, Brilinta requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Do you ship to the United States?

Yes, we do. It usually takes 7 to 18 business days to receive your order from our pharmacy.

Is there a generic for Brilinta?

Yes, there is a generic alternative for this product called ticagrelor.

How quickly does Brilinta work?

Brilinta inhibits platelet aggregation rapidly after the first dose, with significant effects seen within a few hours. However, the full benefit in reducing cardiovascular events is achieved with consistent, long-term use as your doctor prescribes.

What if I miss a dose of Brilinta?

Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for a missed dose.

Blog Post

Could Your Food and Drink Choices Help Dissolve Blood Clots?
Does Grapefruit Affect My Medications?

Latest News

Early Blood Thinner Use After Stroke Reduces Recurrence Risk, Global Study Finds (study published on June 24, 2025)

Similar Drugs in the category of Platelet Aggregation Inhibitors:

Aggrenox Plavix Effient Fragmin Injection Persantine

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers